Get the Stockscreener App
38.08
0.24%
-0.09
Pre-market:
38.50
0.42
+1.10%
Viking Therapeutics Inc stock is traded at $38.08, with a volume of 3.60M.
It is down -0.24% in the last 24 hours and up +44.90% over the past month.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
See More
Previous Close:
$38.17
Open:
$38.5
24h Volume:
3.60M
Relative Volume:
0.56
Market Cap:
$4.28B
Revenue:
-
Net Income/Loss:
$-99.15M
P/E Ratio:
-40.95
EPS:
-0.93
Net Cash Flow:
$-74.25M
1W Performance:
+10.63%
1M Performance:
+44.90%
6M Performance:
+31.90%
1Y Performance:
-47.50%
1-Day Range:
$36.94
$38.88
1-Week Range:
$33.75
$39.57
52-Week Range:
$18.92
$79.10
Viking Therapeutics Inc Stock (VKTX) Company Profile
Name
Viking Therapeutics Inc
Sector
Industry
Phone
858-704-4660
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
38.08 | 4.31B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-25 | Initiated | Canaccord Genuity | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Goldman | Neutral |
| Feb-13-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-07-25 | Initiated | Citigroup | Neutral |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Nov-22-24 | Initiated | B. Riley Securities | Buy |
| Nov-04-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-24 | Initiated | JP Morgan | Overweight |
| Jun-27-24 | Initiated | Morgan Stanley | Overweight |
| May-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-26-24 | Reiterated | Oppenheimer | Outperform |
| Mar-07-24 | Initiated | Jefferies | Buy |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| May-31-23 | Resumed | ROTH MKM | Buy |
| Mar-28-23 | Reiterated | Maxim Group | Buy |
| Mar-17-23 | Initiated | Stifel | Buy |
| Jul-29-21 | Resumed | BTIG Research | Buy |
| May-25-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-05-20 | Initiated | BMO Capital Markets | Outperform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| May-01-20 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-25-19 | Initiated | Stifel | Buy |
| Mar-29-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-14-19 | Reiterated | Maxim Group | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Nov-19-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-18-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-18-18 | Reiterated | Maxim Group | Buy |
| Sep-18-18 | Reiterated | Raymond James | Outperform |
| Jul-20-18 | Initiated | SunTrust | Buy |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-01-18 | Reiterated | Laidlaw | Buy |
| May-31-18 | Reiterated | Maxim Group | Buy |
| Mar-26-18 | Resumed | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | Maxim Group | Buy |
| Nov-21-17 | Initiated | ROTH Capital | Buy |
View All
Viking Therapeutics Inc Stock (VKTX) Latest News
Prediction: The Next Eli Lilly Might Already Be Trading Under $50 - AOL.com
Signal strength of Viking Therapeutics Inc. stock in tech scannersQuarterly Performance Summary & Scalable Portfolio Growth Ideas - newser.com
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Viking Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Levels & Weekly High Momentum Picks - newser.com
Sell Novo Nordisk And Buy Viking Therapeutics (NASDAQ:VKTX) - Seeking Alpha
Can trapped investors hope for a rebound in Viking Therapeutics Inc.July 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
My Top Growth Stock to Buy in November - AOL.com
Viking Therapeutics (VKTX): Assessing Valuation After Shares Jump 28% in the Past Month - Yahoo Finance
Is Viking Therapeutics Inc. (1VT) stock undervalued by metricsJuly 2025 Decliners & Long-Term Growth Plans - newser.com
How Viking Therapeutics Inc. (1VT) stock trades after earningsWatch List & Entry Point Confirmation Signals - newser.com
How Viking Therapeutics Inc. (1VT) stock reacts to stronger dollarJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - newser.com
Should You Buy Viking Therapeutics Before Nov. 5? - The Globe and Mail
Should You Buy Viking Therapeutics Before Nov. 5? - The Motley Fool
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise - Stocktwits
Is Viking Therapeutics Inc. forming a bottoming baseJuly 2025 Catalysts & Low Risk Growth Stock Ideas - newser.com
How hedge fund analytics apply to Viking Therapeutics Inc. stock2025 Winners & Losers & Real-Time Buy Signal Alerts - newser.com
Can Viking Therapeutics Inc. stock hit record highs againMarket Growth Review & Consistent Profit Trading Strategies - newser.com
Why Viking Therapeutics Inc. stock attracts high net worth investors - newser.com
Daymark Wealth Partners LLC Takes $212,000 Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
How Viking Therapeutics Inc. stock trades during market volatilityEarnings Miss & AI Forecast Swing Trade Picks - newser.com
Advanced analytics toolkit walkthrough for Viking Therapeutics Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - newser.com
What makes Viking Therapeutics Inc. stock attractive to growth fundsWeekly Risk Report & Free AI Powered Buy and Sell Recommendations - newser.com
Viking Therapeutics (NASDAQ:VKTX) Trading 6.8% HigherShould You Buy? - MarketBeat
Canaccord Genuity Group Initiates Coverage on Viking Therapeutics (NASDAQ:VKTX) - MarketBeat
Viking Therapeutics (VKTX): Assessing Valuation as VK2735 Clinical Updates Fuel Investor Interest - Sahm
Live market analysis of Viking Therapeutics Inc.Portfolio Return Summary & Verified Swing Trading Watchlists - newser.com
Can Viking Therapeutics Inc. (1VT) stock sustain margin levelsEarnings Performance Report & Low Risk Entry Point Tips - newser.com
3 Promising Growth Stocks That Are Down Around 60% From Their Highs - Yahoo Finance
Heatmap analysis for Viking Therapeutics Inc. and competitors2025 Price Action Summary & Community Driven Trade Alerts - newser.com
What drives Viking Therapeutics Inc 1VT stock priceMACD Trading Signals & Exceptional Profit Ideas - earlytimes.in
Viking Therapeutics, Inc. (VKTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera - Stocktwits
Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences - Investing.com Canada
Viking Therapeutics Faces Leadership Share Sales Amid Analyst Optimism - AD HOC NEWS
Greg Zante Sells 6,185 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock - MarketBeat
Marianna Mancini Sells 6,185 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) CEO Brian Lian Sells 38,989 Shares - MarketBeat
Viking Therapeutics (NASDAQ:VKTX) Director Sells $2,134,200.00 in Stock - MarketBeat
Can Viking Therapeutics (VKTX) Sustain Its Innovation Edge in Obesity Treatments Amid Intensifying Competition? - Sahm
Viking Therapeutics (NASDAQ: VKTX) to present VK2735 data at ObesityWeek and AHA 2025 - Stock Titan
Viking Therapeutics Stock (VKTX) Opinions on Phase 3 Trial Progress and Drug Data - Quiver Quantitative
Canaccord Genuity Initiates Coverage of Viking Therapeutics (VKTX) with Buy Recommendation - Nasdaq
Viking Therapeutics, Inc. (VKTX) Stock Forecasts - Yahoo Finance
Canaccord Genuity Initiates Viking Therapeutics at Buy With $106 Price Target - MarketScreener
Canaccord Genuity Initiates Coverage on Viking Therapeutics (VKT - GuruFocus
Viking Therapeutics Inc Stock (VKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):